Mark E Molitch1, Demetra Rupp, Mercedes Carnethon. 1. Division of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, 303 E. Chicago Ave. (Tarry 15-731), Chicago, Illinois 60611, USA. molitch@northwestern.edu
Abstract
OBJECTIVE: The objective of this study was to determine whether high levels of HDL cholesterol are associated with a lower prevalence of albuminuria RESEARCH DESIGN AND METHODS: We analyzed the lipid profiles of patients with type 1 diabetes of > or = 20 years duration in 42 patients with albuminuria (28 microalbuminuria and 14 macroalbuminuria) and 65 patients without increased albumin excretion before any interventions with either statins or ACE inhibitors. RESULTS: Several characteristics were similar in the two groups: sex, age, duration of diabetes, total cholesterol, LDL cholesterol, and triglycerides. By univariate analysis, significant differences (P < 0.01) were found in HDL cholesterol (albuminuria 1.42 mg/dl, no albuminuria 1.71 mg/dl, P < 0.01), HbA1c (A1C) (albuminuria 8.5%, no albuminuria 7.5%), and proportions with no, background, and proliferative retinopathy (albuminuria 2.4, 16.7, and 81%; no albuminuria 24.6, 52.3, and 23.1%, respectively). When adjusted for age and sex, a 0.26-mmol/l (10-mg/dl) increase in HDL cholesterol is associated with an odds ratio (OR) of 0.70 (95% CI 0.54-0.90) for having albuminuria. In a multivariate model that adjusted for age, sex, diabetes duration, and A1C, for every 0.54-mmol/l (21-mg/dl) increase in HDL cholesterol, patients are approximately half (OR 0.51 [95% CI 0.30-0.86]) as likely to have albuminuria, even after controlling for A1C. CONCLUSIONS: Higher HDL cholesterol levels may be protective against the development of albuminuria in patients with type 1 diabetes. Whether this is due to the HDL cholesterol levels or whether they serve as a marker for some other mechanism remains to be determined.
OBJECTIVE: The objective of this study was to determine whether high levels of HDL cholesterol are associated with a lower prevalence of albuminuria RESEARCH DESIGN AND METHODS: We analyzed the lipid profiles of patients with type 1 diabetes of > or = 20 years duration in 42 patients with albuminuria (28 microalbuminuria and 14 macroalbuminuria) and 65 patients without increased albumin excretion before any interventions with either statins or ACE inhibitors. RESULTS: Several characteristics were similar in the two groups: sex, age, duration of diabetes, total cholesterol, LDL cholesterol, and triglycerides. By univariate analysis, significant differences (P < 0.01) were found in HDL cholesterol (albuminuria 1.42 mg/dl, no albuminuria 1.71 mg/dl, P < 0.01), HbA1c (A1C) (albuminuria 8.5%, no albuminuria 7.5%), and proportions with no, background, and proliferative retinopathy (albuminuria 2.4, 16.7, and 81%; no albuminuria 24.6, 52.3, and 23.1%, respectively). When adjusted for age and sex, a 0.26-mmol/l (10-mg/dl) increase in HDL cholesterol is associated with an odds ratio (OR) of 0.70 (95% CI 0.54-0.90) for having albuminuria. In a multivariate model that adjusted for age, sex, diabetes duration, and A1C, for every 0.54-mmol/l (21-mg/dl) increase in HDL cholesterol, patients are approximately half (OR 0.51 [95% CI 0.30-0.86]) as likely to have albuminuria, even after controlling for A1C. CONCLUSIONS: Higher HDL cholesterol levels may be protective against the development of albuminuria in patients with type 1 diabetes. Whether this is due to the HDL cholesterol levels or whether they serve as a marker for some other mechanism remains to be determined.
Authors: Ian H de Boer; Tessa C Rue; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Wanjie Sun; Bernard Zinman; John D Brunzell; Neil H White; Ronald P Danis; Matthew D Davis; Dean Hainsworth; Larry D Hubbard; David M Nathan Journal: Arch Intern Med Date: 2011-03-14
Authors: Ian H de Boer; Brad C Astor; Holly Kramer; Walter Palmas; Kyle Rudser; Stephen L Seliger; Michael G Shlipak; David S Siscovick; Michael Y Tsai; Bryan Kestenbaum Journal: Atherosclerosis Date: 2007-08-06 Impact factor: 5.162
Authors: Jamie Morton; Sophia Zoungas; Qiang Li; Anushka A Patel; John Chalmers; Mark Woodward; David S Celermajer; Joline W J Beulens; Ronald P Stolk; Paul Glasziou; Martin K C Ng Journal: Diabetes Care Date: 2012-08-13 Impact factor: 19.112